Preferred Label : Anti-PD-L1/Anti-VEGF-A Bispecific Antibody BNT327;
NCIt synonyms : Anti-PD-L1/VEGF-A Bispecific Antibody PM8002; PD-L1 x VEGF-A Bispecific Antibody PM8002; Anti-PD-L1/VEGF-A Bispecific Antibody BNT327; PD-L1 x VEGF-A Bispecific Antibody BNT327; Anti-PD-L1/Anti-VEGF-A Bispecific Antibody PM8002;
NCIt definition : A bispecific antibody targeting both the immunosuppressive ligand programmed cell
death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial
growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic
and antineoplastic activities. Upon administration, anti-PD-L1/anti-VEGF-A bispecific
antibody BNT327 targets and simultaneously binds to both PD-L1 and VEGF-A expressed
on tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell
death protein 1 (PD-1; PDCD1; CD279), inhibits the PD-1-mediated signaling, and inhibits
the PD-1-mediated downregulation of T-cell activation and proliferation. This restores
and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor
cells. The binding of BNT32 to VEGF-A prevents the binding of VEGF-A to VEGF receptor
(VEGFR), thereby preventing the activation of VEGF-A/VEGFR-mediated signaling pathways.
This prevents angiogenesis and may halt tumor cell proliferation. PD-L1 is overexpressed
in many human cancer cell types and plays an important role in the downregulation
of the immune system and tumor evasion from host immunity. VEGF-A is upregulated in
a variety of cancer cell types and plays a crucial role in angiogenesis.;
Molecule name : PM-8002; PM 8002; BNT-327; BNT 327;
NCI Metathesaurus CUI : CL1907083;
Origin ID : C200259;
UMLS CUI : C5854501;
Semantic type(s)
- concept_is_in_subset
- has_target
